Dr Chih-Tsung Yang

Dr. Chih-Tsung Yang is a Research Associate at the Future Industries Institute. His interdisciplinary research expertise is centred on the fields of biomaterials, biosensing, microfluidics and organ-on-a-chip models. His current research is focused on the development of bioengineered human organs-on-a-chip models to evaluate the therapeutic efficiency of nanomedicine and radiation therapy protocols.

Prior to the start of his PhD, he significantly contributed to the liquid biopsy technology that underpinned the successful spin-off of CellMax Life ($15 million from VCs). He joined the University of South Australia as a PhD candidate in 2013 to develop amplification strategies of surface plasmon resonance biosensor towards the improved biosensing for cancer prognostics. The main tangible outcomes include; a biosensor able to identify metastatic tumour cells based on the concept of intracellular micromotion as well as the development of ultrasensitive signal amplification schemes for optical biosensors. His research is published in high quality peer reviewed international journals (72% in top 10% of their field).

Dr. Yang is actively engaged in his research community and is regularly invited to serve as a reviewer for peer-reviewed scientific journals (ACS Biomaterials Science & Engineering, ACS Applied Materials and Interfaces, Sensors, Optical Materials, Plos One and Applied Sciences). He is the UniSA node project leader of the signature project “Development of bioengineered multicellular systems” of the ARC Centre of Excellence for Convergent Bio-Nano Science &Technology (CBNS).

American Chemical Society 2019-

Australian Society of Medical Research 2018-

Australasian Biotechnology 2016-

Australian Nanotechnology Network (ANN) 2013-

Qualifications

• Doctor of Philosophy University of South Australia